Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+or -A33+allele.
The HLA-A11 or -A33 allele is found in approximately 18% or 10% of the Asian population, respectively, but each of which is a minor allele worldwide, and therefore no clinical trials were previously conducted. To develop a therapeutic peptide vaccine for each of them, we investigated immunological responses of advanced cancer patients with the HLA-A11+/A11+(n = 18) or -A33+/A33+(n = 13) allele to personalized peptide vaccine (PPV) regimens. The primary sites of HLA-A11+/A11+ or -A33+/A33+ patients were the colon (n = 4 or 2), stomach (2 or 3), breast (3 or 2), lung and pancreas (2 or 2), and so on. For PPV, a maximum of four peptides were selected from nine different peptides capable of binding to HLA-A11 and -A33 molecules based on the pre-existing peptide-specific IgG responses. There were no severe adverse events related to PPV. At the end of the first cycle, peptide-specific CTL responses were augmented in 4/12 or 2/9 of HLA-A11+/A11+or -A33+/A33+patients, while peptide-specific IgG responses were augmented in 6/14 or 4/10 patients, respectively. Clinical responses consisted of four stable diseases and 14 progressive diseases in HLA-A11+/A11+patients, versus seven and six in -A33+/A33+patients, respectively. Further clinical study of PPV could be recommended because of the safety and positive immunological responses.
Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan.|Cancer Vaccine Center, Kurume University, Kurume, Japan.|Department of Molecular and Internal Medicine School of Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Shinjiro
http://orcid.org/0000-0002-2805-900X
S
Sakamoto
Cancer Vaccine Center, Kurume University, Kurume, Japan.
Satoko
S
Matsueda
Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
Shinzo
S
Takamori
Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
Uhi
U
Toh
Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan.
Masanori
M
Noguchi
Cancer Vaccine Center, Kurume University, Kurume, Japan.
Shigeru
http://orcid.org/0000-0001-6306-4130
S
Yutani
Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan.
Akira
A
Yamada
Cancer Vaccine Center, Kurume University, Kurume, Japan.
Shigeki
S
Shichijo
Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan.
Teppei
T
Yamada
Department of Urology, Kurume University School of Medicine, Kurume, Japan.
Shigetaka
S
Suekane
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.
Kouichiro
K
Kawano
Cancer Vaccine Center, Kurume University, Kurume, Japan.
Masayasu
M
Naitou
Cancer Vaccine Center, Kurume University, Kurume, Japan.|Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Tetsuro
http://orcid.org/0000-0002-2313-8833
T
Sasada
Department of Molecular and Internal Medicine School of Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Noboru
N
Hattori
Hiroshima Cosmopolitan University, Hiroshima, Japan.
Nobuoki
N
Kohno
Cancer Vaccine Center, Kurume University, Kurume, Japan.
Kyogo
K
Itoh
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000595:Amino Acid Sequence; D000740:Anemia / Q000209:etiology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology / Q000378:metabolism; D015234:HLA-A Antigens / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D007970:Leukopenia / Q000209:etiology; D008875:Middle Aged; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D012189:Retrospective Studies; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000378:metabolism; D014611:Vaccination / Q000009:adverse effects / Q000379:methods*; D022223:Vaccines, Subunit / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D055815:Young Adult
D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D015234:HLA-A Antigens; D007074:Immunoglobulin G; D022223:Vaccines, Subunit; D007371:Interferon-gamma
HLA-A11; HLA-A33; IgG; cytotoxic T-Lymphocytes; peptide vaccine